A Skolkovo resident's drug for hepatitis D is recognized as a breakthrough therapy in the USA
The world's first drug for previously incurable hepatitis D, Myrcludex B, created by a resident of the Skolkovo Foundation, received Breakthrough Therapy status from the US Food and Drug Administration. According to the foundation's press service, the medicine was developed by the biotechnological company Hepatera. Myrcludex B is effective for the treatment of not only hepatitis D, but also hepatitis B.